Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

- Memorial Sloan-Kettering Cancer Center Investigators to Assess BSI-201

Therapy in BRCA-Negative Ovarian Cancer Patients -

BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer.

The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.

"We believe BSI-201 holds great promise as a targeted therapy in this difficult-to-treat type of ovarian cancer," said Carol Aghajanian, M.D., co- principal investigator and chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center. "BRCA-negative patients are at higher risk of breast and ovarian cancer because BRCA plays a key role in repairing DNA errors that lead to tumor formation."

Ovarian cancer strikes more than 21,000 women a year in the United States and is one of the most common causes of cancer death in women, killing more than 15,000 annually in the United States. Patients with the hereditable BRCA- negative form of the disease account for about 15 percent of the patient population. Women with defective BRCA genes are also at considerably higher risk of breast cancer.

"We have identified a number of important types of cancer where PARP plays a crucial role in tumor growth, and we believe that BRCA-negative ovarian cancer represents another excellent target for BSI-201," said Barry Sherman, M.D., BiPar's Executive Vice President of Development. "We will soon have patients enrolled in four separate Phase 2 trials of BSI-201, reflecting the breadth of tumor types that could be sensitive to the drug."

The company is currently conducting a Phase 2 trial of BSI-201 in triple- negative breast cancer and is collaborating with the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group, to test BSI-201 in glioblastoma multiforme (GBM), the most common brain cancer in adults. An additional trial in uterine cancer is expected to begin enrollment in the coming weeks. The company also plans to present data from its Phase 1 trials of BSI-201 in solid tumors at the American Society of Clinical Oncology Annual Meeting that begins later this month in Chicago.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
Breaking Medicine Technology:
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel ... thousand words. The good news for single women is that she put all the ... available on April 25th. Joan's insight, personal experiences and sparkling sense of humor have ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
Breaking Medicine News(10 mins):